Form 4 Filing for Celldex Therapeutics, Inc. - KELER TIBOR

This filing details a Form 4 submission for Celldex Therapeutics, Inc. (CLDX), reporting on transactions by KELER TIBOR, EXECUTIVE VP & CSO. On June 25, 2026, Mr. Keler was granted 115,000 Incentive Stock Options (ISOs) with a purchase price of $0.00 per share, exercisable on June 25, 2027, and expiring on June 25, 2036. These options are part of the company's 2021 Omnibus Equity Incentive Plan. The options vest over a period starting with 25% on June 25, 2027, followed by quarterly vesting over the subsequent 12 quarters. The underlying security for these options is the company's Common Stock. Post-transaction, Mr. Keler holds 115,000 shares underlying these options. The filing was signed on June 29, 2026, by Sam Martin as attorney-in-fact for Tibor Keler.